• About WordPress
    • WordPress.org
    • Documentation
    • Learn WordPress
    • Support
    • Feedback
  • Log In
  • Request Membership
Skip to content
Medxy AI Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe
  • Home
  • Specialties
  • Diabetes & Endocrinology
  • Page 13
Continuous Glucose Monitoring in Gestational Diabetes: Insights from the DipGluMo Randomized Controlled Trial in Switzerland
Posted inClinical Updates Diabetes & Endocrinology news Specialties

Continuous Glucose Monitoring in Gestational Diabetes: Insights from the DipGluMo Randomized Controlled Trial in Switzerland

Posted by By MedXY 08/02/2025
The DipGluMo trial found that real-time continuous glucose monitoring does not improve perinatal outcomes versus self-monitoring in gestational diabetes, but is preferred by patients for ease of use.
Read More
Postoperative Radioiodine Ablation in Low-Risk Differentiated Thyroid Cancer: Insights from the IoN Trial
Posted inClinical Updates Diabetes & Endocrinology news Oncology Specialties

Postoperative Radioiodine Ablation in Low-Risk Differentiated Thyroid Cancer: Insights from the IoN Trial

Posted by By MedXY 08/02/2025
The IoN trial demonstrates that postoperative radioiodine ablation can be safely omitted in most patients with low-risk differentiated thyroid cancer after total thyroidectomy, without compromising recurrence-free survival.
Read More
Amycretin: A Novel Unimolecular GLP-1 and Amylin Receptor Agonist for Obesity – Early-Phase Clinical Insights and Broader GLP-1 Drug Development Perspective
Posted inClinical Updates Diabetes & Endocrinology news Specialties

Amycretin: A Novel Unimolecular GLP-1 and Amylin Receptor Agonist for Obesity – Early-Phase Clinical Insights and Broader GLP-1 Drug Development Perspective

Posted by By MedXY 08/02/2025
Amycretin, a new unimolecular GLP-1 and amylin agonist, demonstrated significant weight loss and acceptable tolerability in a phase 1b/2a study, underscoring its potential as an anti-obesity therapy.
Read More
Retatrutide in Type 2 Diabetes and MASLD: Integrative Evidence on Body Composition and Liver Fat Reduction
Posted inClinical Updates Diabetes & Endocrinology news Specialties

Retatrutide in Type 2 Diabetes and MASLD: Integrative Evidence on Body Composition and Liver Fat Reduction

Posted by By MedXY 08/02/2025
Retatrutide, a triple hormone receptor agonist, significantly reduces body fat and liver fat in patients with type 2 diabetes and MASLD, with a favorable safety profile and preservation of lean mass.
Read More
Once-Weekly Insulin Regimens in Type 2 Diabetes: Comparative Efficacy, Safety, and Clinical Implications from COMBINE 3 and QWINT Trials
Posted inClinical Updates Diabetes & Endocrinology news Specialties

Once-Weekly Insulin Regimens in Type 2 Diabetes: Comparative Efficacy, Safety, and Clinical Implications from COMBINE 3 and QWINT Trials

Posted by By MedXY 08/02/2025
Once-weekly insulin regimens (IcoSema, efsitora alfa) demonstrate non-inferior glycemic control compared to daily injections in type 2 diabetes, with advantages in hypoglycemia risk, weight, and injection burden.
Read More
Automated Insulin Delivery in Young Children with Type 1 Diabetes: Insights from the LENNY Trial
Posted inClinical Updates Diabetes & Endocrinology news Specialties

Automated Insulin Delivery in Young Children with Type 1 Diabetes: Insights from the LENNY Trial

Posted by By MedXY 08/02/2025
The LENNY trial demonstrates that the MiniMed 780G automated insulin delivery system improves glycaemic control and maintains safety in children aged 2–6 years with type 1 diabetes.
Read More
Oveporexton: A Promising Orexin Receptor 2 Agonist for Narcolepsy Type 1 – Results from a Phase 2 Randomized Trial
Posted inClinical Updates Diabetes & Endocrinology news Specialties

Oveporexton: A Promising Orexin Receptor 2 Agonist for Narcolepsy Type 1 – Results from a Phase 2 Randomized Trial

Posted by By MedXY 08/02/2025
Oveporexton, an oral orexin receptor 2–selective agonist, demonstrated significant improvements in wakefulness and cataplexy in narcolepsy type 1 patients over 8 weeks, with manageable adverse events.
Read More
Inebilizumab for Generalized Myasthenia Gravis: Results from a Phase 3 Randomized Trial
Posted inClinical Updates Diabetes & Endocrinology news Specialties

Inebilizumab for Generalized Myasthenia Gravis: Results from a Phase 3 Randomized Trial

Posted by By MedXY 08/01/2025
A phase 3 trial shows inebilizumab, a CD19+ B-cell depleting antibody, improves function and reduces disease severity in generalized myasthenia gravis without increasing serious adverse events.
Read More
FDA Approves Once-Weekly Skytrofa (Lonapegsomatropin-tcgd) for Adult Growth Hormone Deficiency: Clinical Implications and Evidence Review
Posted inClinical Updates Diabetes & Endocrinology news Specialties

FDA Approves Once-Weekly Skytrofa (Lonapegsomatropin-tcgd) for Adult Growth Hormone Deficiency: Clinical Implications and Evidence Review

Posted by By MedXY 07/31/2025
Skytrofa, a once-weekly injectable growth hormone, is FDA-approved for adult GHD, offering improved adherence and positive metabolic outcomes. Clinical trials show superior efficacy and favorable safety compared to daily somatropin.
Read More
Advances in Obesity and Diabetes Management: Highlights from ADA 2025
Posted inDiabetes & Endocrinology news Specialties

Advances in Obesity and Diabetes Management: Highlights from ADA 2025

Posted by By MedXY 07/31/2025
New weight-loss drug combinations, oral semaglutide cardiovascular outcomes, inhaled insulin for type 1 diabetes, and benefits of switching from diet drinks to water were key ADA 2025 findings.
Read More
Veligrotug Emerges as a Promising Therapy for Thyroid Eye Disease: Insights from the THRIVE and THRIVE-2 Trials
Posted inClinical Updates Diabetes & Endocrinology news Ophthalmology Specialties

Veligrotug Emerges as a Promising Therapy for Thyroid Eye Disease: Insights from the THRIVE and THRIVE-2 Trials

Posted by By MedXY 07/31/2025
Veligrotug demonstrates robust efficacy and manageable safety in both active and chronic thyroid eye disease, positioning itself as a potential alternative to teprotumumab based on phase 3 THRIVE trial data.
Read More
GLP-1 Receptor Agonists and Risk of GERD in Type 2 Diabetes: Clinical Implications from a Large Population-Based Cohort Study
Posted inClinical Updates Diabetes & Endocrinology Gastroenterology news Specialties

GLP-1 Receptor Agonists and Risk of GERD in Type 2 Diabetes: Clinical Implications from a Large Population-Based Cohort Study

Posted by By MedXY 07/31/2025
GLP-1 receptor agonists modestly increase the risk of GERD and its complications compared to SGLT-2 inhibitors in type 2 diabetes patients, highlighting the need for vigilant symptom monitoring.
Read More
Weekend Warrior Exercise Patterns: Comparable Cardiometabolic Protection to Regular Activity in Diabetes and MASLD
Posted inClinical Updates Diabetes & Endocrinology news Specialties

Weekend Warrior Exercise Patterns: Comparable Cardiometabolic Protection to Regular Activity in Diabetes and MASLD

Posted by By MedXY 07/31/2025
Accumulating 150 minutes of moderate-to-vigorous physical activity weekly, either as a 'weekend warrior' or in regular sessions, significantly reduces mortality and cardiometabolic risk in adults with diabetes and MASLD.
Read More
GLP-1 Receptor Agonists and Dementia Risk in Older Adults With Type 2 Diabetes: Insights From a Target Trial Emulation
Posted inClinical Updates Diabetes & Endocrinology news Specialties

GLP-1 Receptor Agonists and Dementia Risk in Older Adults With Type 2 Diabetes: Insights From a Target Trial Emulation

Posted by By MedXY 07/31/2025
A large-scale emulated trial found no clear overall reduction in dementia risk with GLP-1 receptor agonists versus DPP-4 inhibitors in older adults with type 2 diabetes, though age-specific effects warrant further investigation.
Read More
Preterm Birth Linked to Long-Term Adult Cardiometabolic and Mental Health Risks: New U.S. Cohort Study
Posted inCardiology Diabetes & Endocrinology Medical News news Specialties

Preterm Birth Linked to Long-Term Adult Cardiometabolic and Mental Health Risks: New U.S. Cohort Study

Posted by By MedXY 07/30/2025
Adults born preterm face significantly higher risks of cardiometabolic abnormalities and internalizing mental health problems by age 35, according to a new U.S. cohort study.
Read More
Top U.S. Hospitals for Diabetes and Endocrinology: Interpreting the 2025–2026 U.S. News Rankings
Posted inDiabetes & Endocrinology Medical News news Specialties

Top U.S. Hospitals for Diabetes and Endocrinology: Interpreting the 2025–2026 U.S. News Rankings

Posted by By MedXY 07/30/2025
A critical analysis of the 2025–2026 U.S. News rankings for diabetes and endocrinology care, examining methodology, clinical impact, and implications for patient care and referral.
Read More
Redefining Obesity: Impact of the ‘Clinical Obesity’ Framework on Global Prevalence Estimates
Posted inCardiology Diabetes & Endocrinology Medical News news Specialties

Redefining Obesity: Impact of the ‘Clinical Obesity’ Framework on Global Prevalence Estimates

Posted by By MedXY 07/30/2025
A new, function-driven definition of “clinical obesity” dramatically lowers global obesity prevalence rates compared to BMI-based estimates, raising implications for disease surveillance, prevention, and healthcare policy.
Read More
Understanding Macronutrients: Their Role in Obesity and Weight Management
Posted inCardiology Diabetes & Endocrinology news Specialties

Understanding Macronutrients: Their Role in Obesity and Weight Management

Posted by By MedXY 07/29/2025
Explore the impact of macronutrients on obesity, focusing on carbohydrates, proteins, and fats, and learn strategies for effective weight management.
Read More
Revolutionizing Diabetes Management in Pregnancy with Hybrid Closed-Loop Technology
Posted inDiabetes & Endocrinology news OB/GYN & Women's Health Specialties

Revolutionizing Diabetes Management in Pregnancy with Hybrid Closed-Loop Technology

Posted by By MedXY 07/29/2025
A groundbreaking trial highlights how hybrid closed-loop systems improve glycemic control for pregnant women with type 1 diabetes, offering enhanced maternal and fetal health outcomes.
Read More
Maternal Diet and Childhood Diabetes: Unveiling the Link
Posted inDiabetes & Endocrinology news Specialties

Maternal Diet and Childhood Diabetes: Unveiling the Link

Posted by By MedXY 07/29/2025
A large Danish study reveals that pro-inflammatory diets during pregnancy may increase the risk of type 1 diabetes in offspring, emphasizing the importance of maternal nutrition.
Read More

Posts pagination

Previous page 1 … 11 12 13 14 Next page
  • Offering Multiple Appropriate Alternatives Increases Primary Care Physicians’ Adoption of Recommended Care: A Randomized Trial
  • Pediatric In‑Hospital Cardiac Arrest: Why Adult Resuscitation Lessons Don’t Fully Translate — Airway, Epinephrine, and the Limits of Training
  • Condition-Specific Growth Charts and a New Medical Therapy for Alagille Syndrome: Implications for Growth Assessment and Symptom Control
  • Prehospital Postintubation Hypotension Strongly Linked to 30‑Day Mortality After Severe Traumatic Brain Injury — Especially in Isolated TBI
  • Sự Tiếp Xúc với Đói Lớn trong Tuổi Thơ của Người Di Dân Trung Quốc Liên Quan Mạnh mẽ đến Bệnh Tiểu Đường và Huyết Áp Cao sau này – Nhưng Không Phải Nhập Viện Tim Mạch
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号
  • English
  • 日本語
  • Tiếng Việt
  • 中文

aging Alzheimer's disease artificial intelligence atrial fibrillation biomarkers blood pressure breast cancer cardiovascular disease cardiovascular health cardiovascular risk chronic kidney disease clinical trial clinical trials critical care depression diabetes epidemiology exercise health heart failure Hypertension immunotherapy inflammation MASLD mental health metformin Mortality multiple myeloma nutrition obesity older adults Pediatrics Physical Activity Pregnancy prevention prostate cancer public health randomized clinical trial randomized controlled trial randomized trial screening targeted therapy type 2 diabetes weight loss women's health

Your health, we care

Copyright 2025 — Medxy AI. All rights reserved.
Scroll to Top
Sign in